Stay updated on Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The top of the Study Details page now shows Revision: v3.3.4, replacing the previous Revision: v3.3.3 banner.
    Difference
    0.0%
    Check dated 2026-01-14T03:13:38.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    Locations section added showing Florida as a study site; Florida Locations entry and the HHS Vulnerability Disclosure link were removed. Revision: v3.3.3.
    Difference
    0.2%
    Check dated 2025-12-23T22:23:04.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    Revision history updated: added v3.3.2 and removed v3.2.0; no changes to the study content.
    Difference
    0.0%
    Check dated 2025-11-25T11:48:32.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    Removed the government funding lapse notice from the page. The study details and related information remain unchanged.
    Difference
    0.3%
    Check dated 2025-11-18T07:14:09.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    The page now displays sponsor-related entries such as the H. Lee Moffitt Cancer Center and Research Institute and includes a 'Helpful Links Provided by' section with a link to the Moffitt Clinical Trials site. This enhances access to sponsor resources and related trial information on the study page.
    Difference
    0.1%
    Check dated 2025-11-11T02:57:54.000Z thumbnail image
  8. Check
    75 days ago
    Change Detected
    Summary
    No significant changes to the study details were detected between versions; any differences are likely cosmetic formatting or layout adjustments. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T21:20:17.000Z thumbnail image

Stay in the know with updates to Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page.